ARUP Test
|
Indications for Use
|
Therapeutic Rangea/Toxic Level
|
Carbamazepine Epoxide and Total 0092211
|
Optimize drug therapy and monitor patient adherence
|
Carbamazepine-10,11 Epoxide
Therapeutic range – not well established
Toxic – >15 µg/mL
Total carbamazepine
Therapeutic range – 4-12 µg/mL
Toxic – >15 µg/mL
|
Carbamazepine, Free and Total, Serum or Plasma 2011763
|
Optimize drug therapy and monitor patient adherence
|
Total carbamazepine
Therapeutic range – 4-12 µg/mL
Toxic – >15 µg/mL
Free carbamazepine
Therapeutic range – 1-3 µg/mL
Toxic – >3.8 µg/mL
Percent free carbamazepine
8-35%
|
Carbamazepine, Total 0090260
|
Optimize drug therapy and monitor patient adherence
|
Total carbamazepine
Therapeutic range – 4-12 µg/mL
Toxic – >15 µg/mL
|
Clobazam Quantitative, Serum or Plasma 2008597
|
Optimize drug therapy and monitor patient adherence
|
n/a
|
Ethosuximide, Serum or Plasma 2010358
|
Optimize drug therapy and monitor patient adherence
|
Therapeutic range – 40-100 µg/mL
Toxic – >150 µg/mL
|
Felbamate 0094030
|
Optimize drug therapy and monitor patient adherence
|
Therapeutic range – not well established
Toxic – >200 µg/mL
|
Gabapentin 0090057
|
Optimize drug therapy and monitor patient adherence
|
Therapeutic range – 2-20 µg/mL
Toxic – not well established
|
Gabapentin, Urine 2012227
|
Useful for general testing in contexts of compliance and/or abuse
Preferred test to follow up presumptive results
|
n/a
|
Keppra (Levetiracetam) 0098627
|
Optimize drug therapy and monitor patient adherence
|
Therapeutic range – 12-46 µg/mL
Toxic – not well established
|
Lacosamide, Serum or Plasma 2003182
|
Optimize drug therapy and monitor patient adherence
|
Therapeutic range – not well established; suggested range 5-10 µg/mL
Dose-related range – 2.5-18 µg/mL
Toxic – not well established
|
Lamotrigine 0090177
|
Optimize drug therapy and monitor patient adherence
|
Therapeutic range – 2.5-15 µg/mL
Toxic – not well established
|
Methsuximide Metabolite, Serum or Plasma 3000251
|
Optimize drug therapy and monitor patient adherence
|
Normethsuximide – methsuximide metabolite
Therapeutic range – 10-40 µg/mL
|
Oxcarbazepine or Eslicarbazepine Metabolite (MHD) 0098834
|
Optimize drug therapy and monitor patient adherence
|
Therapeutic range – 3-35 µg/mL
Toxic – >40 µg/mL
|
Perampanel Quantitative, Serum or Plasma 2013025
|
Optimize drug therapy and monitor patient adherence
|
n/a
|
Phenobarbital 0090230
|
Optimize drug therapy and monitor patient adherence
|
0-2 months
Therapeutic range – 15-30 µg/mL
Toxic – ≥40.1 µg/mL
3 months and older
Therapeutic range – 15-40 µg/mL
Toxic – ≥50.1 µg/mL
|
Phenobarbital, Total/Free/Bound, Serum or Plasma 0091551
|
Optimize drug therapy and monitor patient adherence
|
n/a
|
Phenytoin, Free and Total 0090141
|
Preferred test for therapeutic drug management in patients with renal failure or conditions that may alter albumin concentrations
|
Phenytoin, Total
Therapeutic range – 10-20 µg/mL
Toxic – >30 µg/mL
Phenytoin, Free Level
Therapeutic – 1-2.5 µg/mL
Toxic – >2.5 µg/mL
Phenytoin, Percent Free
8-14%
|
Phenytoin, Free 2010481
|
Therapeutic drug management for patients with renal failure or conditions that may alter albumin concentrations
|
Therapeutic range – 1-2.5 µg/mL
Toxic – >2.5 µg/mL
|
Phenytoin 0090090
|
Optimize drug therapy and monitor patient adherence
This test can be ordered when fosphenytoin is administered
|
0-2 months
Therapeutic – 6-14 µg/mL
Toxic – ≥14.1 µg/mL
3 months and older
Therapeutic – 10-20 µg/mL
Toxic – ≥30.1 µg/mL
|
Pregabalin, Serum or Plasma 2011609
|
Optimize drug therapy and monitor patient adherence
|
Therapeutic range – not well established
Toxic – not well established
|
Primidone and Metabolite 0090202
|
Optimize drug therapy and monitor patient adherence; the active metabolite of primidone is phenobarbital
|
Phenobarbital
0-2 months
Therapeutic range – 15-30 µg/mL
Toxic – ≥40.1 µg/mL
3 months and older
Therapeutic range – 15-40 µg/mL
Toxic – ≥50.1 µg/mL
Primidone (Mysoline)
5-12 µg/mL
|
Rufinamide, Serum or Plasma 2003176
|
Optimize drug therapy and monitor patient adherence
|
Therapeutic range – not well established
Dose-related range – 3-30 µg/mL
Toxic – not well established
|
Tiagabine, Serum or Plasma 0091541
|
Optimize drug therapy and monitor patient adherence
|
n/a
|
Topiramate 0070390
|
Optimize drug therapy and monitor patient adherence
|
Therapeutic range – 5-20 µg/mL
Toxic – not well established
|
Valproic Acid, Free and Total 0099310
|
Preferred test for therapeutic drug management in patients with renal failure or conditions that may alter albumin concentrations
|
Valproic Acid, Total
Therapeutic range – 50-125 µg/mL
Toxic – >150 µg/mL
Valproic Acid, Free
Therapeutic range – 7-23 µg/mL
Toxic – >30 µg/mL
Valproic Acid, Percent Free
5-18 percent
|
Valproic Acid 0090290
|
Optimize drug therapy and monitor patient adherence
|
Toxic – ≥151 µg/mL
|
Vigabatrin Quantitative, Serum or Plasma 2011039
|
Optimize drug therapy and monitor patient adherence
|
n/a
|
Zonisamide 0097908
|
Optimize drug therapy and monitor patient adherence
|
Therapeutic range – not well established
Toxic – >80 µg/mL
|
aThe therapeutic range is based on serum predose (trough) draw at steady-state concentration
|